Update file drug-data.tsx

src/data/drug-data.tsx

@@ -38,7 +38,7 @@ export const drugdata: (Array<DrugDatensatz>)  = [
                 text: ["Active ingredient(s): Combination of elexacaftor/tezacaftor/ivacaftor \n Indications: For CF patients aged 2 years and older with at least one F508del mutation à 85 % of CF patients \n Mechanism: Elexacaftor and tezacaftor act as correctors on misfolded CFTR and permit delivery to the cell surface, thereby improving the channel density at the plasma membrane, while ivacaftor as a potentiator acts on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5]. \n Administration: Oral tablets \n Approval: Approved by the EMA in 2020 "] },
             {
                 title: "Symdeko",
-                text: ["Active ingredient(s): Combination of tezacaftor and ivacaftor \n Indications: For CF patients aged 6 years and older with specific mutations in combination with F508del or with two copies of F508del mutation \n Mechanism: Tezacaftor acts as a corrector on misfolded CFTR and permit delivery to the cell surface, thereby improving the channel density at the plasma membrane, while ivacaftor as a potentiator acts on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5] \n Administration: Oral tablets \n Approval: Approved by the EMA in 2018"]
+                text: ["Active ingredient(s): Combination of tezacaftor and ivacaftor", "Indications: For CF patients aged 6 years and older with specific mutations in combination with F508del or with two copies of F508del mutation", "Mechanism: Tezacaftor acts as a corrector on misfolded CFTR and permit delivery to the cell surface, thereby improving the channel density at the plasma membrane, while ivacaftor as a potentiator acts on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5]", "Administration: Oral tablets", "Approval: Approved by the EMA in 2018"]
             },
         ]
     },